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ABSTRACT
The incidence of adenocarcinoma in Barrett’s esophagus has been
increasing rapidly over the past decades. Neoplastic progression is char-
acterized by three well-defined premalignant stages: metaplasia, low-
grade dysplasia, and high-grade dysplasia. A genome-wide overview,
based on comparative genomic hybridization, was performed, evaluating
30 Barrett’s adenocarcinomas and 25 adjacent precursors, i.e., 6 meta-
plasias, 9 low-grade dysplasias, and 10 high-grade dysplasias. The fre-
quency of losses and gains significantly increased in the subsequent stages
of malignant transformation. Losses of 5q21-q23, 9p21, 17p12–13.1,
18q21, and Y were revealed in low-grade dysplasias. This was followed by
loss of 7q33-q35 and gains of 7p12-p15, 7q21-q22, and 17q21 in high-grade
dysplasias along with high-level amplification (HLA) of 7q21 and 17q21.
In the invasive cancers, additional losses of 3p14-p21, 4p, 4q, 8p21,
13q14-q31, 14q24.3-q31, 16q21-q22, and 22q as well as gains of 3q25-q27,
8q23–24.1, 12p11.2–12, 15q22-q24, and 20q11.2-q13.1 were distinguished
along with HLAs of 8p12-p22 and 20q11.2-q13.1. Approximately one-
third of the alterations in the dysplasias were also found in the adjacent
adenocarcinomas, illustrating that multiple clonal lineages can be present
in Barrett’s esophagus. Novel findings include loss on 7q, gain on 12p, and
the observation of several HLAs in high-grade dysplasias. Furthermore,
loss of 7q33-q35 was found to represent a significant distinction between
low-grade and high-grade dysplasia (P 5 0.01), whereas loss of 16q21-q22
and gain of 20q11.2-q13.1 were disclosed to significantly discriminate
between high-grade dysplasia and adenocarcinoma (P 5 0.02 and
P 5 0.03, respectively). This inventory of genetic aberrations increases our
understanding of malignant transformation in Barrett’s esophagus and
might provide useful biomarkers for disease progression.
INTRODUCTION
Barrett’s esophagus arises after replacement of squamous epithe-
lium, lining the normal esophagus, with columnar epithelium. This
generally occurs in the distal part of the esophagus, probably as a
result of gastric refluxes (1–3). It occurs in 11–14% of chronic
gastroesophageal reflux disease patients (2). Esophageal adenocarci-
noma almost exclusively develops in columnar-lined Barrett’s esoph-
agus. Barrett’s esophagus is considered a precursor condition for the
development of adenocarcinoma, which includes the following suc-
cessive stages: metaplasia, low-grade dysplasia, and high-grade dys-
plasia. Over the past decades, the incidence of Barrett-related adeno-
carcinoma has increased rapidly and is most frequently diagnosed in
elderly white males (4). These adenocarcinomas have an extremely
poor prognosis, since metastases are frequently present at time of
diagnosis (5).
Cytogenetic analyses of Barrett’s adenocarcinomas showed fre-
quent losses of chromosomes 4, 18, 21, and Y, and frequent gain of 14
and 20. Frequent rearrangements were seen on 1p, 3q, 11p, and 22q
(6). In situ hybridization analyses using chromosome-specific centro-
meric probes demonstrated gains for chromosomes 6, 7, 8, 11, and 12
as well as loss for 17 and Y in these cancers (7–9). Thus far, few
comparative genomic hybridization studies have been reported on
adenocarcinomas arising at and around the gastroesophageal junction,
including Barrett-related adenocarcinoma. Frequent losses were re-
ported on 4pq, 5q, 9p, 14q, 16q, 17p, 18q, 21q, and Y, whereas
frequent gain was seen on 1q, 3q, 5p, 6p, 7pq, 8q, 12q, 13q, 15q, 17q,
18p, 20q, and Xpq (10–14). Loss of 14q31-q32.1 was detected in a
significantly higher frequency in Barrett-related adenocarcinoma than
in gastric cardia cancers (13). Furthermore, we described a subset of
shared alterations in a case of multifocal Barrett’s adenocarcinoma
and adjacent high-grade dysplasia (14). Loss of heterozygosity de-
tected frequent allelic imbalance on 4q, 5q, 9p, 13q, 16q, 17p, and 18q
in adenocarcinomas, suggesting involvement of the APC3, MCC,
CDKN2A, retinoblastoma 1, TP53, and DCC genes (15–23). In ad-
dition, mutations were revealed in TP53 and APC (18). No mutations
were found in DPC4, making involvement of DPC4 unlikely (24).
Loss of heterozygosity performed on premalignant lesions showed
imbalances at 5q, 17p, and 18q (16, 18, 20, 25). An increasing
frequency of the latter imbalances was detected in the successive
stages of metaplasia, low-grade dysplasia, high-grade dysplasia, and
adenocarcinoma (16). Recently, loss of heterozygosity was used to
study evolution of neoplastic cell lineages in Barrett’s esophagus,
demonstrating that premalignant lesions situated around the tumor
consisted of different clonal lineages (26). Protein expression studies
have shown that subpopulations of Barrett’s adenocarcinoma can have
elevated expression of oncogenes ERBB2 and EGFR, whereas only
few cases of elevated expression were detected in dysplasia (27, 28).
However, activation of the SRC oncogene (29) and aberrant expres-
sion of fragile histidine triad was reported in metaplasias (30). More-
over, polyploidy and aneuploidy have been reported as an early event
in Barrett’s esophagus (31).
Today, we are not able to predict malignant progression from
Barrett’s esophagus to cancer. Therefore, it would be useful to gain
more insight into the genetics underlying this process by creating an
inventory of the alterations in Barrett’s esophagus and Barrett’s ade-
nocarcinoma by means of a genome-wide overview.
MATERIALS AND METHODS
Patient Material. The study was comprised of 30 Barrett-related adeno-
carcinomas of the distal esophagus and 25 Barrett’s mucosa specimens, adja-
cent to the adenocarcinomas. The 30 adenocarcinoma samples consisted of 4
stage I, 5 stage IIA, 4 stage IIB, 5 stage III, and 12 stage IV cancers, classified
according to the Tumor-Node-Metastasis classification (32). The average age
of the group of 30 patients at the time of resection was 65 years, with a male
to female ratio of 5:1. The 25 Barrett’s esophagus samples consisted of 10
high-grade dysplasias, 9 low-grade dysplasias, and 6 metaplasias. All but two
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samples were collected by manual microdissection of Formalin-fixed, paraffin-
embedded tissue sections. The use of archival, Formalin-fixed tissue sections
allowed for a precise selection of representative tumor and adjacent preneo-
plastic areas. Microdissection of the selected areas was performed by scraping
successive 10-mm tissue sections. Before microdissecting, the slides were
deparaffinated using standard methods and stained for 30 s with hematoxylin.
After dehydration by an ethanol series, the slides were treated with 2.5%
glycerol for 30 s to facilitate dissection. Scraping was performed using a stereo
microscope and a 0.4- 3 12-mm hollow needle. The presence of the lesion was
confirmed on H&E-stained tissue sections of the upper and lower boundaries.
Two fresh-frozen samples (two metaplasias) were laser microdissected and the
DNA was randomly amplified by degenerate oliogonucleotide-primed PCR
(33).
DNA Isolation and Labeling. Isolation of DNA from the Formalin-fixed,
paraffin-embedded material was performed using standard procedures. Test
DNA with fragment size ,1 kb was labeled using the Universal Linkage
System biotin labeling kit (Kreatech Diagnostics, Amsterdam, The Nether-
lands) according to the manufacturer’s directions (34). Test DNA with larger
DNA fragment sizes was labeled with biotin by nick translation (Nick Trans-
lation System; Life Technologies, Inc., Gaithersburg, MD). Likewise, male
reference DNA (Promega Corporation, Madison, WI) was labeled by nick
translation with digoxigenin (Boehringer Mannheim, Indianapolis, IN).
Comparative Genomic Hybridization. Comparative genomic hybridiza-
tion was essentially performed according to the procedure described by Kal-
lioniemi et al. (35) with some modifications (34). Images were acquired with
an epifluorescent microscope (Leica DM; Leica, Rijswijk, The Netherlands)
equipped with a charge-coupled device camera (Photometrics Inc., Tucson,
AZ), three single excitation filters, a multiband pass dichroic mirror, and
emission filters. For comparative genomic hybridization analysis, Quips XL
software from Vysis (version 3.1.1; Vysis Inc., Downers Grove, IL) was used.
Loss of DNA sequences was defined as chromosomal regions where the mean
green to red ratio was below 0.85, while gain was defined as chromosomal
regions where the ratio was above 1.15. These values were based on series of
normal controls (34). Furthermore, each hybridization included a separate
normal male versus female control. Approximately 90% of all paraffin samples
were analyzable; five samples were repeated to confirm results. A high-level
amplification probably representing an amplicon was seen as a distinct peak
(ratio above 1.5). At least 8–10 metaphases were used for the analysis of gains
and losses per sample. The data were collected in chromosomal ideograms.
Assignment of candidate genes to smallest regions of overlap was done by
screening the genecards database of the Weizmann Institute4 (36).
Statistical Analysis. Chromosomal regions were subjected to statistical
analysis if their frequency of imbalance for loss or gain was $25% in the
adenocarcinoma group. This threshold was empirically chosen at a level where
“background” is avoided. Percentages of aberrations between low-grade dys-
plasia and high-grade dysplasia, as well as high-grade dysplasia and adeno-
carcinoma, were evaluated using Fisher’s exact test, after it was verified that
there were no statistical associations within patients between the results found
in adenocarcinoma and in premalignant lesion. Comparison of the subsequent
stages of tumorigenesis without (metaplasia, low-grade dysplasia, and high-
grade dysplasia) and with adenocarcinoma (metaplasia, low-grade dysplasia,
high-grade dysplasia, and adenocarcinoma) regarding prevalences of various
characteristics was done using the x2 test for trend of percentages. Correlation
coefficients (rs) given are Spearman’s rank tests. P 5 0.05 (two sided) was
considered to be the limit of significance.
RESULTS
Comparative genomic hybridization was performed on 30 Barrett-
related adenocarcinomas and 25 adjacent Barrett epithelia, i.e., 6
metaplasias, 9 low-grade dysplasias, and 10 high-grade dysplasias
(Table 1). The observed aberrations were collected in separate ideo-
grams, which are shown in Fig. 1. In all 30 adenocarcinomas, multiple
alterations were observed (average of 11.0 altered chromosomes per
tumor). Frequent loss ($25% of the tumors) was detected, in decreas-
ing order of frequency, on 18q (63%), Y (60%), 9p (53%), 4p (47%),
4q (40%), 16q (40%), 7q (37%), 14q (37%), 13q (33%), 17p (30%),
3p (30%), 22q (30%), 5q (27%), and 8p (27%). Frequent gain ($25%
of the tumors) was seen, in decreasing order of frequency, on 20q
(53%), 8q (47%), 7p (37%), 7q (37%), 15q (30%), 3q (27%), 12p
(27%), and 17q (27%). Many high-level amplifications were dis-
closed: five at 7q21 and 8p12-p22, three at 10q21.3-q25 and 20q11.2-
q13.1, two at 17q21, and one at 1q21, 3q26.3, 8q24.1, 12p11.2, and
15q22-q24. One patient displayed three different high-level amplifi-
cations within one adenocarcinoma, whereas two other patients
showed two within the same cancer. Minimal overlapping regions
were assigned to pinpoint areas where putative oncogenes or tumor
suppressor genes reside. Minimal overlapping regions for loss in the
adenocarcinomas were 3p14-p21, 5q21-q23, 7q33-q35, 8p21, 9p21,
13q22–32, 14q24.3-q31, 16q21-q22, 17p12-p13.1, and 18q21. Mini-
mal overlapping regions for gain were 3q25-q27, 7p12-p15, 7q21-
q22, 8q23-q24.1, 12p11.2-p12, 17q21, and 20q11.2-q13.1.
No alterations were detected in metaplasia by comparative genomic
hybridization. The dysplasias were then screened with emphasis on
aberrations seen frequently in the adenocarcinomas (see above). An
average of 3.2 altered chromosomes per sample was observed in
low-grade dysplasia, whereas in 2 of the 9 low-grade dysplasias no
alterations were found. Frequent loss on relevant chromosome arms
was detected on 5q (22%), 9p (33%), 17p (22%), and Y (22%). No
recurrent gains were seen in low-grade dysplasias. Multiple alter-
ations, with an average of 7.6 altered chromosomes per sample, were
found in all 10 high-grade dysplasias. Frequent loss was observed, in
decreasing order of frequency, on 18q (70%), 7q (60%), 5q (60%), Y
(40%), 9p (40%), 17p (40%), and 12q (30%). Frequent gain was seen
on 13q (40%), 7p (30%), 7q (30%), and 17q (30%). In addition, three
high-level amplifications were detected: two on 7q21.3 and one on
17q21. The following minimal overlapping regions were found in
dysplasia: 5q21-q31, 7q33-q35, 9p21, 17p12-p13.1, and 18q21 could
be assigned for losses, whereas for gains 7q21-q22 and 17q21 were
revealed.
A gradual increase was found in the mean number of aberrant
chromosomes, chromosomes showing loss and chromosomes show-
ing gain in the successive stages of metaplasia, low-grade dysplasia,
high-grade dysplasia, and adenocarcinoma (Spearman’s rank test, all
P , 0.001; see Fig. 2). Significant trends regarding increased preva-
lences in Barrett’s esophagus (metaplasia, low-grade dysplasia, and
high-grade dysplasia sequence) were loss of 5q21-q31 (P 5 0.01),
7q33-q35 (P , 0.01), and loss of 18q21 (P , 0.01). Extension of the
sequence with the adenocarcinomas revealed significant trends for
increased prevalence of loss of 4p (P , 0.01), 4q (P 5 0.02),
7q33-q35 (P 5 0.03), 9p21 (P 5 0.02), 13q14-q31 (P 5 0.01),
14q24.3-q31 (P , 0.01), 16q21-q22 (P , 0.01), 18q21 (P , 0.01),
22q (P 5 0.01), and Y (P , 0.01). Likewise, significant trends for
gain were seen on 7p12-p15 (P 5 0.03), 7q21-q22 (P 5 0.03),
8q23-q24 (P , 0.01), 12p11.2-p12 (P 5 0.03), and 20q11.2-q13.1
(P , 0.01) and for high-level amplification (P , 0.01). About
one-third of the aberrations present in the dysplasia were also found in
the adjacent carcinoma (see Table 1). Only patients 22 and 24 had
conserved all aberrations of the premalignant lesions in the adjacent
adenocarcinomas. These findings illustrate that premalignant lesions
surrounding the adenocarcinoma consist of several different clonal
lineages (26). Furthermore, all three high-level amplifications de-
tected in high-grade dysplasia could also be distinguished in the
adjacent adenocarcinoma. Comparison of increasing frequencies of
high-grade dysplasia and adenocarcinoma revealed two significant
differences, i.e., loss of 16q21-q22 (P 5 0.02) and gain of 20q11.2-
q13.1 (P 5 0.03). In addition, a significant increase was observed
between low-grade dysplasia and high-grade dysplasia for loss of
7q33-q35 (P 5 0.01).4 World Wide Web URL: http://bioinfo.weizmann.ac.il/cards.
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Table 1 Chromosomal aberrations identified by comparative genomic hybridization
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Table 1 Continued
a Adenocarcinomas were classified according to the Tumor-Node-Metastasis classification (32); HGD, high-grade dysplasia; LGD, low-grade dysplasia; M, metaplasia.
b Bold print, aberration identified in both adenocarcinoma and dysplasia of the same patient; NA, no aberrations detected.
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DISCUSSION
The cancer-related genes fragile histidine triad, CTNNB1 (b-cate-
nin), APC, MCC, CDKN2A, CTSB (cathepsin B), F37/esophageal
cancer-related leucine-zipper motif (FEZ1), retinoblastoma 1, CDH1
(E-cadherin), TP53, DCC, EGFR, SRC, and ERBB2 are located within
the smallest regions of overlap on frequently altered chromosome
arms discriminated in this study. Moreover, these genes showed
allelic imbalances, mutations, or altered expression in Barrett-related
adenocarcinoma (15, 18, 22, 24, 25, 27, 29, 30, 37–41). Other
candidate genes, such as caspase 2 (CASP2), tumor necrosis factor-
related apoptosis-induced ligand receptor B (TNFRS10B), TSHR, v-
Ki-ras2 Kirsten rat sarcoma 2 viral oncogene (KRAS2), hepatocyte
growth factor, v-myc myelocytomatosis (MYC), and insulin-like
growth factor 1 receptor (IGF1R), can be selected based on location
and oncogenic or tumor-suppressive potential in general, e.g.,
TNFSR10B is of interest, since it is expressed in the proliferating
compartment of colonic crypt mucosa and loss of this locus has been
reported for colon cancer (42). Several members of the cadherin gene
family, e.g., CDH1 (E-cadherin) are located on 16q21-q22 (43).
Reduced expression levels of proteins involved in the E-cadherin-
catenin complex have been described in Barrett’s esophagus and
adenocarcinoma (37, 41). Reduced levels of E-cadherin, a-catenin,
and b-catenin in Barrett-related adenocarcinoma correlated with a
poor prognosis (37, 41). Our comparative genomic hybridization
showed frequent losses in the vicinity of CDH1 (16q22) and CTNNB1
(3p21.3-p22), the latter coding for b-catenin. In addition, aberrant
copy numbers were detected of gene loci harboring genes like APC,
EGFR, IGF1R, and SRC, which can influence maintenance and ex-
pression levels of proteins involved in the cadherin-catenin complex
(43). It has been shown that subpopulations of Barrett’s adenocarci-
noma have elevated or overexpression of ERBB2 (27, 28), possibly a
gene dosage effect. Although a high frequency of loss is observed on
chromosome 4, it was not possible to assign a smallest region of
overlap. This could be due to a high density of involved tumor
suppressor gene loci on chromosome 4, which is supported by a recent
loss of heterozygosity study. The authors described that at least three
loci on the long arm of chromosome 4 were frequently altered in
Barrett’s adenocarcinoma (17).
Fig. 1. Losses and gains were collected in chro-
mosomal ideograms to summarize DNA copy num-
ber changes detected by comparative genomic hy-
bridization. A bar on the left side of the ideogram
represents loss; a bar on the right side represents
gain of a chromosomal region. Open boxes within
bars represent high-level amplifications. Chromo-
somal ideograms were constructed for adenocarci-
nomas (n 5 30; A) and dysplasias (n 5 19; B), the
latter consisting of 10 high-grade dysplasias and
nine low-grade dysplasias. No alterations were seen
in metaplasia. Black bars in B, aberrations of the
high-grade dysplasias; gray bars, aberrations of the
low-grade dysplasias.
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No aberrations were detected in metaplasia by comparative
genomic hybridization, which is in contrast with a recently published
comparative genomic hybridization study on Barrett’s esophagus (10).
The latter study reported both losses and gains in metaplasias without
dysplasia. We could not find alterations in metaplasias of both archi-
val and fresh-frozen specimens. The absence of genomic aberrations
in intestinal metaplasia without dysplasia is, to our opinion, in agree-
ment with the low cancer risk reported for Barrett’s esophagus (44).
Moreover, loss of heterozygosity studies of metaplasia have been
inconclusive in finding alterations. One report described lack of allelic
imbalance in metaplasia at the TP53, APC, and CDKN2A gene loci
(18), whereas another study detected allelic imbalance at the APC
gene locus in metaplasia only if isolated adjacent to adenocarcinoma
(25). A third report described allelic imbalance in metaplasia, but this
might be due to the inclusion of “indefinite for dysplasia” specimens
(16). However, as in our study, an increase in loss of heterozygosity
was detected at the loci of TP53, APC, and DCC in the successive
stages of metaplasia, low-grade dysplasia, high-grade dysplasia, and
adenocarcinoma (16). Evaluation of the losses found in dysplasias on
the long arm of chromosome 5 suggests that there might be two
deleted regions. These two loci, 5q21-q22 and 5q31-q34, contain
candidate genes APC, MCC, (5q21-q22) and CTNNA1 (5q31), respec-
tively. The latter codes for a-catenin, which is part of the E-cadherin-
catenin complex. Finally, loss of 7q33-q35 might include CASP2, a
gene involved in the regulation of apoptosis (45).
In conclusion, this study has revealed a variety of not only known,
but also novel aberrations involved in malignant transformation of
Barrett’s esophagus, e.g., high frequency loss on 7q, gain on 12p, and
high-level amplifications on 7q and 17q in high-grade dysplasias.
Some of the alterations might be useful biomarkers to discriminate
between the different stages of neoplastic progression. Loss of 16q21-
q22 and gain of 20q11.2-q13.1 were disclosed as potent discrimina-
tors between high-grade dysplasia and adenocarcinoma. Moreover,
loss of 7q33-q35 appeared to be a novel marker to distinguish between
low-grade dysplasia and high-grade dysplasia.
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